Powered by OpenAIRE graph
Found an issue? Give us feedback

Clinical phase II trial evaluating the efficacy of systemic Mesenchymal Stromal Cell (MSC) injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications (pelvic radiation disease, PRD) refractory to standard therapy. Acronym : PRISME (Pelvic Radiation dISease and MEsenchymal stromal cells)

Funder: Institut National du CancerProject code: INCa-DGOS-7278 Call for proposal: PHRC13
Funded under: PHRC

Clinical phase II trial evaluating the efficacy of systemic Mesenchymal Stromal Cell (MSC) injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications (pelvic radiation disease, PRD) refractory to standard therapy. Acronym : PRISME (Pelvic Radiation dISease and MEsenchymal stromal cells)

Powered by OpenAIRE graph
Found an issue? Give us feedback

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

All Research products
arrow_drop_down
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::f6cd44df9bd44a7c73a27e8ff3c6a156&type=result"></script>');
-->
</script>
For further information contact us at helpdesk@openaire.eu

No option selected
arrow_drop_down